Cargando…
Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis
Systemic sclerosis (SSc) is a chronic multisystem disorder characterized by fibrosis and autoimmunity. Interleukin (IL)-31 has been implicated in fibrosis and T helper (Th) 2 immune responses, both of which are characteristics of SSc. The exact role of IL-31 in SSc pathogenesis is unclear. Here we s...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511151/ https://www.ncbi.nlm.nih.gov/pubmed/34642338 http://dx.doi.org/10.1038/s41467-021-26099-w |
_version_ | 1784582715841970176 |
---|---|
author | Kuzumi, Ai Yoshizaki, Ayumi Matsuda, Kazuki M. Kotani, Hirohito Norimatsu, Yuta Fukayama, Maiko Ebata, Satoshi Fukasawa, Takemichi Yoshizaki-Ogawa, Asako Asano, Yoshihide Morikawa, Kyojiro Kazoe, Yutaka Mawatari, Kazuma Kitamori, Takehiko Sato, Shinichi |
author_facet | Kuzumi, Ai Yoshizaki, Ayumi Matsuda, Kazuki M. Kotani, Hirohito Norimatsu, Yuta Fukayama, Maiko Ebata, Satoshi Fukasawa, Takemichi Yoshizaki-Ogawa, Asako Asano, Yoshihide Morikawa, Kyojiro Kazoe, Yutaka Mawatari, Kazuma Kitamori, Takehiko Sato, Shinichi |
author_sort | Kuzumi, Ai |
collection | PubMed |
description | Systemic sclerosis (SSc) is a chronic multisystem disorder characterized by fibrosis and autoimmunity. Interleukin (IL)-31 has been implicated in fibrosis and T helper (Th) 2 immune responses, both of which are characteristics of SSc. The exact role of IL-31 in SSc pathogenesis is unclear. Here we show the overexpression of IL-31 and IL-31 receptor A (IL-31RA) in dermal fibroblasts (DFs) from SSc patients. We elucidate the dual role of IL-31 in SSc, where IL-31 directly promotes collagen production in DFs and indirectly enhances Th2 immune responses by increasing pro-Th2 cytokine expression in DFs. Furthermore, blockade of IL-31 with anti-IL-31RA antibody significantly ameliorates fibrosis and Th2 polarization in a mouse model of SSc. Therefore, in addition to defining IL-31 as a mediator of fibrosis and Th2 immune responses in SSc, our study provides a rationale for targeting the IL-31/IL-31RA axis in the treatment of SSc. |
format | Online Article Text |
id | pubmed-8511151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-85111512021-10-29 Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis Kuzumi, Ai Yoshizaki, Ayumi Matsuda, Kazuki M. Kotani, Hirohito Norimatsu, Yuta Fukayama, Maiko Ebata, Satoshi Fukasawa, Takemichi Yoshizaki-Ogawa, Asako Asano, Yoshihide Morikawa, Kyojiro Kazoe, Yutaka Mawatari, Kazuma Kitamori, Takehiko Sato, Shinichi Nat Commun Article Systemic sclerosis (SSc) is a chronic multisystem disorder characterized by fibrosis and autoimmunity. Interleukin (IL)-31 has been implicated in fibrosis and T helper (Th) 2 immune responses, both of which are characteristics of SSc. The exact role of IL-31 in SSc pathogenesis is unclear. Here we show the overexpression of IL-31 and IL-31 receptor A (IL-31RA) in dermal fibroblasts (DFs) from SSc patients. We elucidate the dual role of IL-31 in SSc, where IL-31 directly promotes collagen production in DFs and indirectly enhances Th2 immune responses by increasing pro-Th2 cytokine expression in DFs. Furthermore, blockade of IL-31 with anti-IL-31RA antibody significantly ameliorates fibrosis and Th2 polarization in a mouse model of SSc. Therefore, in addition to defining IL-31 as a mediator of fibrosis and Th2 immune responses in SSc, our study provides a rationale for targeting the IL-31/IL-31RA axis in the treatment of SSc. Nature Publishing Group UK 2021-10-12 /pmc/articles/PMC8511151/ /pubmed/34642338 http://dx.doi.org/10.1038/s41467-021-26099-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kuzumi, Ai Yoshizaki, Ayumi Matsuda, Kazuki M. Kotani, Hirohito Norimatsu, Yuta Fukayama, Maiko Ebata, Satoshi Fukasawa, Takemichi Yoshizaki-Ogawa, Asako Asano, Yoshihide Morikawa, Kyojiro Kazoe, Yutaka Mawatari, Kazuma Kitamori, Takehiko Sato, Shinichi Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis |
title | Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis |
title_full | Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis |
title_fullStr | Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis |
title_full_unstemmed | Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis |
title_short | Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis |
title_sort | interleukin-31 promotes fibrosis and t helper 2 polarization in systemic sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511151/ https://www.ncbi.nlm.nih.gov/pubmed/34642338 http://dx.doi.org/10.1038/s41467-021-26099-w |
work_keys_str_mv | AT kuzumiai interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT yoshizakiayumi interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT matsudakazukim interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT kotanihirohito interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT norimatsuyuta interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT fukayamamaiko interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT ebatasatoshi interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT fukasawatakemichi interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT yoshizakiogawaasako interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT asanoyoshihide interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT morikawakyojiro interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT kazoeyutaka interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT mawatarikazuma interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT kitamoritakehiko interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis AT satoshinichi interleukin31promotesfibrosisandthelper2polarizationinsystemicsclerosis |